466 related articles for article (PubMed ID: 28653280)
1. Clozapine as a Model for Antipsychotic Development.
Nucifora FC; Mihaljevic M; Lee BJ; Sawa A
Neurotherapeutics; 2017 Jul; 14(3):750-761. PubMed ID: 28653280
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the evidence of clozapine's anti-aggressive effects.
Frogley C; Taylor D; Dickens G; Picchioni M
Int J Neuropsychopharmacol; 2012 Oct; 15(9):1351-71. PubMed ID: 22339930
[TBL] [Abstract][Full Text] [Related]
3. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
4. Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process.
Dickens D; Rädisch S; Chiduza GN; Giannoudis A; Cross MJ; Malik H; Schaeffeler E; Sison-Young RL; Wilkinson EL; Goldring CE; Schwab M; Pirmohamed M; Nies AT
Mol Pharm; 2018 Aug; 15(8):3557-3572. PubMed ID: 29944835
[TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of clozapine: involvement of trace amine pathways in C. elegans and M. musculus.
Karmacharya R; Lynn SK; Demarco S; Ortiz A; Wang X; Lundy MY; Xie Z; Cohen BM; Miller GM; Buttner EA
Brain Res; 2011 Jun; 1393():91-9. PubMed ID: 21529784
[TBL] [Abstract][Full Text] [Related]
6. Clozapine versus other atypical antipsychotics for schizophrenia.
Asenjo Lobos C; Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Leucht S
Cochrane Database Syst Rev; 2010 Nov; (11):CD006633. PubMed ID: 21069690
[TBL] [Abstract][Full Text] [Related]
7. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy].
Ewald HL; Mors NP; Rosenberg R
Ugeskr Laeger; 1996 Jun; 158(25):3601-3. PubMed ID: 8693618
[TBL] [Abstract][Full Text] [Related]
8. Unique Effects of Clozapine: A Pharmacological Perspective.
Khokhar JY; Henricks AM; Sullivan EDK; Green AI
Adv Pharmacol; 2018; 82():137-162. PubMed ID: 29413518
[TBL] [Abstract][Full Text] [Related]
9. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.
Pardis P; Remington G; Panda R; Lemez M; Agid O
J Psychopharmacol; 2019 Oct; 33(10):1187-1198. PubMed ID: 31347436
[TBL] [Abstract][Full Text] [Related]
10. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.
Siskind D; McCartney L; Goldschlager R; Kisely S
Br J Psychiatry; 2016 Nov; 209(5):385-392. PubMed ID: 27388573
[TBL] [Abstract][Full Text] [Related]
11. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.
Kapur S; McClelland RA; VanderSpek SC; Wadenberg ML; Baker G; Nobrega J; Zipursky RB; Seeman P
Neuroreport; 2002 May; 13(6):831-5. PubMed ID: 11997696
[TBL] [Abstract][Full Text] [Related]
12. Classics in chemical neuroscience: clozapine.
Wenthur CJ; Lindsley CW
ACS Chem Neurosci; 2013 Jul; 4(7):1018-25. PubMed ID: 24047509
[TBL] [Abstract][Full Text] [Related]
13. The presynaptic component of the serotonergic system is required for clozapine's efficacy.
Yadav PN; Abbas AI; Farrell MS; Setola V; Sciaky N; Huang XP; Kroeze WK; Crawford LK; Piel DA; Keiser MJ; Irwin JJ; Shoichet BK; Deneris ES; Gingrich J; Beck SG; Roth BL
Neuropsychopharmacology; 2011 Feb; 36(3):638-51. PubMed ID: 21048700
[TBL] [Abstract][Full Text] [Related]
14. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?
Carpenter WT; Zito JM; Vitrai J; Volavka J
Biol Psychiatry; 1998 Jan; 43(2):79-83. PubMed ID: 9474440
[TBL] [Abstract][Full Text] [Related]
15. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
16. Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies.
Porter JH; Prus AJ
Psychopharmacology (Berl); 2009 Apr; 203(2):279-94. PubMed ID: 18795269
[TBL] [Abstract][Full Text] [Related]
17. [Leponex, 10 years after -- a clinical review].
Llorca PM; Pere JJ
Encephale; 2004; 30(5):474-91. PubMed ID: 15627052
[TBL] [Abstract][Full Text] [Related]
18. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.
Arranz MJ; Collier DA; Munro J; Sham P; Kirov G; Sodhi M; Roberts G; Price J; Kerwin RW
Neurosci Lett; 1996 Oct; 217(2-3):177-8. PubMed ID: 8916101
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the pharmacotherapy of schizophrenia.
Borison RL
Harv Rev Psychiatry; 1997; 4(5):255-71. PubMed ID: 9385002
[TBL] [Abstract][Full Text] [Related]
20. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.
Masuda T; Misawa F; Takase M; Kane JM; Correll CU
JAMA Psychiatry; 2019 Oct; 76(10):1052-1062. PubMed ID: 31365048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
